Search results
Earnings call: Agios Pharmaceuticals outlines robust pipeline and financial health By Investing.com
Investing.com· 3 days agoThe company highlighted positive Phase 3 ENERGIZE study results for its drug mitapivat in treating...
3 No-Brainer Stocks to Buy in May
Motley Fool via Yahoo Finance· 4 hours agoThe big biotech already has an approved product in two of those markets. Gene-editing therapy Casgevy is a one-and-done functional cure for sickle cell...
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Zacks via Yahoo Finance· 2 days agoAgios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark,...
Agios Pharmaceuticals Reports Q1 2024 Earnings: Narrower Loss than Expected with Strong Revenue ...
GuruFocus.com via Yahoo Finance· 3 days agoProduct Pipeline: Positive Phase 3 results for mitapivat in non-transfusion-dependent thalassemia...
Agios Pharmaceuticals Inc (AGIO) (Q1 2024) Earnings Call Transcr
Guru Focus· 3 days agoAgios Pharmaceuticals Inc (AGIO, Financial) reported positive data from the Phase 3 Energize study...
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
InvestorPlace· 22 hours agoThis excellent opportunity that biotech stocks present can provide investors with potentially...
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
Motley Fool via Yahoo Finance· 3 days agoCRISPR Therapeutics CRISPR Therapeutics is a gene-editing specialist. The company's lone product on...
Novo Nordisk: Growth Is Still A Better Choice
GuruFocus.com via Yahoo Finance· 6 days agoSo, its most promising developments are amycretin, etavopivat and CagriSema, which demonstrate competitive advantages relative to "gold standards" in the...
TIME100 Health: Stuart Orkin
Time via Yahoo News· 3 days ago“But no one had any clue what that really meant; it was kind of a Disney fantasy.” Orkin focused his attention on the hemoglobin gene, which is mutated...
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 5 days agoConsequently, in early 2024, VRTX and CRISPR Therapeutics announced that the FDA has expanded the...